PRF Technologies Ltd. (PRFX): Cash & Equivalents
$3.12M
As of 2025-12-31
-8.6%
3-year compound annual growth
-27.6%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.12M | -26.7% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $4.26M | -46.9% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $8.03M | +95.9% | 2026-03-26, Balance as of period end |
| 2022-12-31 | $4.10M | -75.2% | 2025-04-07, Balance as of period end |
| 2021-12-31 | $16.54M | +5.5% | 2024-02-29, Balance as of period end |
| 2020-12-31 | $15.68M | n/m | 2023-03-15, Balance as of period end |
| 2019-12-31 | $941.0K | n/a | 2021-03-18, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $3.12M | -26.7% |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | $215.2K | -17.8% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $5.89M | -33.5% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $3.0K | -99.8% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $60.18M | -43.0% |
| Genelux Corp (GNLX) | 2025-12-31 | $5.33M | -37.7% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $58.7K | -9.5% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $43.76M | +18.5% |
| Lunai Bioworks Inc. (LNAI) | 2026-06-30 | $1.71M | n/m |
Compare PRFX, BDPT, TLPH, IBO side by side · Screen every company in Pharmaceutical Preparations ↗